A 12-month, prospective, observational study of ranibizumab in treatment-naive Taiwanese patients with neovascular age-related macular degeneration: the RACER study.

ABSTRACT:

Background

The current National Health Insurance scheme in Taiwan reimburses 3 initial plus 4 additional injections of ranibizumab 0.5 mg for eligible patients with neovascular age-related macular degeneration (nAMD). The Ranibizumab AMD Clinical Efficacy in Real-world practice (RACER) study aimed to observe the effectiveness of ranibizumab injections under this reimbursement system.

Methods

RACER was a 12-month, prospective, observational study conducted in treatment-naïve, adult Taiwanese patients with nAMD. Patients received intravitreal ranibizumab 0.5 mg injections in adherence with local prescribing information.

Results

Of 161 patients enrolled, 114 (70.8%) completed the 12-month study. Overall, patients received a mean (standard deviation [SD]) of 4.3 (1.7) ran

SUBMITTER: Wu WC 

PROVIDER: S-EPMC7687747 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature